Generic Name and Formulations:
Linagliptin 5mg; tabs.
Boehringer Ingelheim and Lilly
Indications for TRADJENTA:
Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy. Limitations of use: not for treatment of type 1 diabetes or diabetic ketoacidosis. Not studied in patients with a history of pancreatitis.
5mg once daily.
<18yrs: not established.
Dipeptidyl peptidase-4 (DPP-4) inhibitor.
Monitor for signs/symptoms of pancreatitis; discontinue if suspected. History of angioedema to other DPP-4 inhibitors. Discontinue if a serious hypersensitivity reaction is suspected. Pregnancy (Cat.B). Nursing mothers.
Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.
Nasopharyngitis, hypoglycemia, arthralgia, back pain, headache; hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, exfoliative skin conditions, bronchial hyperreactivity), myalgia, pancreatitis.
Enterohepatic (80%), renal (5%).
- 5mg tablets (Qty:30)
- appx. price $346.00
- Necessary Procedure Leads to Assault and Battery Charges
- Certain Antibiotics May Up Diabetes Risk
- FDA: Life-Threatening Interaction Possible Between Antivirals, Amiodarone
- Study: Abuse, Addiction, Poisoning Diagnoses Decrease with Reformulated Oxycontin
- Study: Pregnant, Breastfeeding Women Not Consuming Enough of This Nutrient
- Public Health Emergency Declared in IN Following HIV Outbreak
- Study: Hospital Readmissions, Length of Stay Greater for C. diff Patients
- Does the Aviation Industry Need Better Mental Health Screening?
- National Strategy to Fight Superbugs Released by the White House
- Gene Mutation May Explain Severe Flu in Healthy Children